#Singapore #Berlin #Immunotherapy #HPV cancer #SCG142

SCG Cell Therapy Presents Groundbreaking Clinical Results for SCG142 at ESMO 2025

SCG Cell Therapy Pte Ltd, a forward-thinking biotechnology company, has initiated a substantial leap in the field of immunotherapy with their recent presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin. On October 18, 2025, SCG showcased pivotal first-in-human clinical trial results of SCG142, a groundbreaking treatment targeting HPV-related carcinomas.

The clinical success of SCG142 is underpinned by its innovative design as a T-cell receptor-engineered therapy, specifically designed to confront human papillomavirus (HPV) infections. The Phase I trial, identified as NCT06544720, aimed to assess SCG142's safety, tolerability, and preliminary efficacy in patients with recurrent or metastatic cancers linked to HPV. Notably, SCG142 employs a unique TGFβRII-41BB chimeric switch receptor, optimizing the immune response against the targeted tumors.

The study focused on a cohort of patients who were confirmed to be HLA-A*0201-positive and had either HPV16 or HPV52-associated carcinomas. Candidates in this trial had demonstrated progression on or intolerance to previous systemic therapies. Preliminary results from the data cut-off indicated that all seven patients treated experienced tumor shrinkage, leading to a remarkable disease control rate (DCR) of 100%. Noteworthy is that four patients saw a greater than 30% reduction in tumor size, which included two confirmed and two unconfirmed partial responses (PR).

These findings were echoed by Prof. Dr. Yang Li, esteemed Director of Medical Oncology at The First Affiliated Hospital of Guangxi Medical University, who remarked, "SCG142 represents a novel approach to TCR T cell therapy focused on HPV, showcasing significant clinical promise. The observed tumor shrinkage across all participants is incredibly encouraging and underscores SCG142's potential efficacy."

SCG142’s development benefits significantly from SCG's proprietary GianTCR(TM) platform, which has been instrumental in isolating high-affinity and high-avidity natural TCRs. This combination not only enhances the potency against solid tumors tied to infections but also minimizes the risk of off-target effects, addressing a common concern in cancer immunotherapy.

In addition to SCG142, SCG Cell Therapy is also making strides with SCG101, a targeted therapy aimed at treating hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV). The expanding pipeline of SCG signifies a commitment to addressing infectious diseases and their malignancies, focusing on HPV, HBV, and EBV infections.

The public health implications of HPV cannot be understated; it stands as the predominant sexually transmitted infection globally, contributing to a staggering 690,000 cancers yearly. HPV infections serve as a precursor to some of the most prevalent and deadly cancers, specifically cervical and anal cancers, making advancements in treatment options critical.

SCG Cell Therapy stands at the intersection of innovation and necessity in the biomedical landscape, committed to fostering the development of novel immunotherapies for infectious diseases and the cancers they incite. With ongoing and future clinical trials, SCG continues to aim for breakthroughs that hold the potential to redefine treatment paradigms for patients burdened by HPV-related cancers.

As the results of SCG142 are released into the public sphere, stakeholders across the board—from patients to medical professionals—are bestowed with renewed hope in addressing the significant health challenge posed by HPV-related cancers. For more insights into SCG's initiatives and research, visit SCG Cell Therapy.